Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 19/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.59 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359010 | 0.93 | PIK3CB (0.59) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL11961143 | 0.86 | PIK3CB (0.62) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL1680281 | 0.84 | PIK3CA (0.84) | PIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL11961139 | 0.82 | PIK3CB (0.44) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL1680649 | 0.80 | PIK3CB (0.53) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL1681396 | 0.78 | PIK3CB (0.59) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL2810461 | 0.78 | PIK3CA (0.80) | PIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL11961134 | 0.78 | PIK3CB (0.49) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG | |
| SCHEMBL2811275 | 0.76 | PIK3R1 (1.00) | PIK3CBPIK3CDPIK3CAPIK3R1 | |
| Zstk-474 SCHEMBL373282 | 0.75 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | claimed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | claimed |
| EP-2483272-A2 | PI3K (DELTA) SELECTIVE INHIBITORS | Xcovery Holding Company LLC (US) | 2012-08-08 | — | — | EP | claimed |
| WO-2011041399-A2 | PI3K (DELTA) SELECTIVE INHIBITORS | TYROGENEX, INC. (US) | 2011-04-07 | — | — | WO | claimed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | disclosed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | disclosed |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC | 2012-08-09 | — | — | US | disclosed |
| WO-2011041399-A2 | PI3K (DELTA) SELECTIVE INHIBITORS | TYROGENEX, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | PIK3CB 6/4885PIK3CD 1/4885PIK3CA 2/4885 |
| US-20120202805-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | PIK3CB 6/4885PIK3CD 1/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.